PLUR

Pluristem Therapeutics Inc. (PSTI) - 10-Q Summary

Business Context and Reporting Period

Company: Pluristem Therapeutics Inc. (formerly A.I. Software Inc.)
Reporting Period: Quarter ended September 30, 2008
Status: Development Stage Company
Business: Development of adherent stromal cells production technology and commercialization of cell therapy products. The company has not generated any revenues since inception and relies on private placements and R&D grants for funding.

Key Financial Metrics

Debt & Liquidity: Total current liabilities were $853,000. The company holds no long-term debt obligations other than accrued severance pay and a minor long-term obligation of $33,000. Liquidity is maintained through equity financing.

Material Changes vs. Prior Period

• Research & Development (R&D): Net R&D expenses increased 43% to $1.193 million from $0.837 million year-over-year. This increase was driven by higher salary and subcontractor costs due to expanded research activity, partially offset by a decrease in stock-based compensation and reduced participation from the Israeli Office of the Chief Scientist.
• General & Administrative (G&A): G&A expenses decreased 36% to $1.003 million from $1.557 million. The reduction is primarily attributed to a significant drop in stock-based compensation expenses ($0.938M to $0.381M) resulting from a decline in the company's stock price.
• Financial Income/Expense: Shifted from a net financial income of $0.114 million in Q3 2007 to a net financial expense of $0.046 million in Q3 2008, largely due to losses on the sale of marketable securities.
• Cash Position: Cash and cash equivalents increased by $1.655 million to $1.978 million, driven by proceeds from equity offerings and the sale of marketable securities.

Guidance, Outlook, and Risks

• Outlook: Management estimates operating cash expenses for the next 12 months to be approximately $6.0 million. The company does not expect to generate product revenues for at least three years.
• Capital Needs: The company anticipates needing to raise additional funds before achieving cash flow from operations. There is substantial doubt about the company's ability to continue as a going concern if financing is not obtained.
• Cost Reduction: Effective November 1, 2008, cash compensation for all management and directors was reduced by 10% for six months, to be partially offset by restricted stock issuance.
• Key Milestones: Filing an IND package with the FDA, scaling up 3-D PluriX Bioreactor operations, and initiating Phase I clinical trials.
• Risks: Reliance on private placements for funding; potential dilution of existing shareholders; failure to obtain regulatory approvals; and the possibility of ceasing operations if financing is unavailable.

Investor Verification Checklist

• Going Concern Status: Verify the company's ability to secure the estimated $6.0 million needed for the next 12 months given the accumulated deficit of $28.2 million.
• Equity Dilution: Review the impact of recent private placements (August and September 2008) and the potential for further dilution required to fund operations.
• Revenue Timeline: Confirm the realistic timeline for the first Phase I clinical trial and FDA IND filing, as product revenue is not expected for at least three years.
• Stock-Based Compensation: Monitor the volatility of stock-based compensation expenses, which significantly impacted G&A expenses in the prior period due to stock price fluctuations.
• Regulatory Compliance: Note the potential legal implications regarding the May 2007 Agreement's minimum price provision following the reverse stock split and subsequent share issuances.